Claris Lifesciences has received an Abbreviated New Drug Application (ANDA) approval for Levofloxacin Injection; having strength of 25mg/ ml in 20 ml vials in the United States of America (US). Levofloxacin Injection is an anti-infective drug administered on adults suffering from infection such as Pneumonia, Acute Bacterial Sinusitis or Complicated Urinary Tract Infection, etc. The intravenous route of administration is considered advantageous to the patient.
Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.
